<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034173</url>
  </required_header>
  <id_info>
    <org_study_id>FIRE-5</org_study_id>
    <nct_id>NCT04034173</nct_id>
  </id_info>
  <brief_title>Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation</brief_title>
  <official_title>FIRE-5 -Study: Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present hypothesis is that anti-EGFR agents are active in tumors with low-level RAS&#xD;
      mutation when the majority of tumor cells is still sensitive. While response rate may be high&#xD;
      and may reflect sensitivity to anti-EGFR agents, PFS is anticipated to be shorter than in RAS&#xD;
      wild-type patients due to the faster development of resistance when sensitive cells are&#xD;
      eradicated and when the RAS-mutant anti-EGFR resistant clones become predominant.&#xD;
&#xD;
      The characteristics of low-level RAS mutant tumors would be:&#xD;
&#xD;
        -  Objective response rate (ORR) high (reflecting the sensitive clone)&#xD;
&#xD;
        -  Progression-free survival (PFS) short (reflecting the more rapid outgrowth of RAS mutant&#xD;
           clones)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>up to 60 months</time_frame>
    <description>As primary endpoint ORR according to RECIST 1.1 will be evaluated separately for each arm of patients with defined low-frequency RAS mutation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 60 months</time_frame>
    <description>PFS, separately for each arm of patients with defined low-frequency RAS mutation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 60 months</time_frame>
    <description>OS, separately for each arm of patients with defined low-frequency RAS mutation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigation of Early Tumor shrinkage (ETS) as an alternative early-on-treatment predictor of treatment efficacy</measure>
    <time_frame>up to 48 months</time_frame>
    <description>ETS, separately for each group of patients with defined low-frequency RAS mutation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigation of Depth of Response (DpR) to define the nadir of tumour response</measure>
    <time_frame>up to 48 months</time_frame>
    <description>DpR, separately for each arm of patients with defined low-frequency RAS Mutation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Treatment Related Cancer</condition>
  <arm_group>
    <arm_group_label>RAS mutations frequency &lt;= 7%</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1&#xD;
*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.&#xD;
Followed by FOLFIRI regimen&#xD;
Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1&#xD;
Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1&#xD;
5-FU 400 mg/m² BSA, bolus, D1&#xD;
5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2&#xD;
q day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RAS mutation frequency &gt;7% to &lt;=14%</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1&#xD;
*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.&#xD;
Followed by FOLFIRI regimen&#xD;
Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1&#xD;
Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1&#xD;
5-FU 400 mg/m² BSA, bolus, D1&#xD;
5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2&#xD;
q day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RAS mutation frequency &gt;14% to &lt;=20%</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1&#xD;
*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.&#xD;
Followed by FOLFIRI regimen&#xD;
Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1&#xD;
Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1&#xD;
5-FU 400 mg/m² BSA, bolus, D1&#xD;
5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2&#xD;
q day 14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1&#xD;
*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.</description>
    <arm_group_label>RAS mutation frequency &gt;14% to &lt;=20%</arm_group_label>
    <arm_group_label>RAS mutation frequency &gt;7% to &lt;=14%</arm_group_label>
    <arm_group_label>RAS mutations frequency &lt;= 7%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1</description>
    <arm_group_label>RAS mutation frequency &gt;14% to &lt;=20%</arm_group_label>
    <arm_group_label>RAS mutation frequency &gt;7% to &lt;=14%</arm_group_label>
    <arm_group_label>RAS mutations frequency &lt;= 7%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic acid</intervention_name>
    <description>Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1</description>
    <arm_group_label>RAS mutation frequency &gt;14% to &lt;=20%</arm_group_label>
    <arm_group_label>RAS mutation frequency &gt;7% to &lt;=14%</arm_group_label>
    <arm_group_label>RAS mutations frequency &lt;= 7%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2</description>
    <arm_group_label>RAS mutation frequency &gt;14% to &lt;=20%</arm_group_label>
    <arm_group_label>RAS mutation frequency &gt;7% to &lt;=14%</arm_group_label>
    <arm_group_label>RAS mutations frequency &lt;= 7%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed, UICC stage IV metastatic adenocarcinoma of the colon or&#xD;
             rectum&#xD;
&#xD;
          -  Primarily non-resectable metastases or surgical resection refused by the patient&#xD;
&#xD;
          -  RAS mutation determined by the local pathology&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Patients suitable for chemotherapy administration&#xD;
&#xD;
          -  Patient's written declaration of consent obtained&#xD;
&#xD;
          -  Estimated life expectancy &gt; 3 months&#xD;
&#xD;
          -  Presence of at least one measurable reference lesion according to the RECIST 1.1&#xD;
             criteria&#xD;
&#xD;
          -  Primary tumor tissue available and patient consents to storage and molecular and&#xD;
             genetic profiling of tumor material. Molecular profiling of blood samples is&#xD;
             optionally performed.&#xD;
&#xD;
          -  Adequate bone marrow function:&#xD;
&#xD;
               -  Leukocytes ≥ 3.0 x 109/L with neutrophils ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Thrombocytes ≥ 100 x 109/L&#xD;
&#xD;
               -  Haemoglobin ≥ 5.6 mmol/L (equivalent to 9 g/dL)&#xD;
&#xD;
          -  Adequate hepatic function:&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  ALAT and ASAT ≤ 2.5 x ULN (in the presence of hepatic metastases, ALAT and ASAT ≤&#xD;
                  5 x ULN)&#xD;
&#xD;
          -  Adequate renal function:&#xD;
&#xD;
             ▫ Creatinine clearance (calculated according to Cockcroft and Gault) ≥ 50 mL/min&#xD;
&#xD;
          -  No previous chemotherapy for metastatic disease. Patient with need of immediate&#xD;
             treatment (high tumor load, symptoms) may have received one application of FOLFIRI&#xD;
             prior to study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous chemotherapy for metastatic disease with the exception of one cycle of&#xD;
             FOLFIRI (e.g. while waiting for the result of RAS mutation frequency).&#xD;
&#xD;
          -  Patients planned to be treated with FOLFOX or another oxaliplatin-based regimen as&#xD;
             first-line treatment&#xD;
&#xD;
          -  Primarily resectable metastases and the patient agrees to resection&#xD;
&#xD;
          -  Grade III or IV heart failure (NYHA classification)&#xD;
&#xD;
          -  Medical or psychological impairments associated with restricted ability to give&#xD;
             consent or not allowing conduct of the study&#xD;
&#xD;
          -  Previous chemotherapy for the colorectal cancer with the exception of adjuvant&#xD;
             treatment, completed at least 6 months before entering the study&#xD;
&#xD;
          -  Participation in an investigational clinical study or experimental drug treatment&#xD;
             within 30 days prior to study inclusion or within a period of 5 half-lives of the&#xD;
             substances administered in the investigational clinical study or during an&#xD;
             experimental drug treatment prior to inclusion in the study, depending on which period&#xD;
             is longest&#xD;
&#xD;
          -  Known hypersensitivity or allergic reaction to any of the following substances:&#xD;
             5-fluorouracil, folinic acid, panitumumab, irinotecan, and chemically related&#xD;
             substances and/or hypersensitivity to any of the excipients of any of the&#xD;
             aforementioned substances including known hypersensitivity reactions to monoclonal&#xD;
             antibodies NCI CTCAE Grade ≥ 3.&#xD;
&#xD;
          -  Known hypersensitivity to Chinese hamster ovary cell (CHO) - cellular products or&#xD;
             other recombinant human or humanised monoclonal antibodies&#xD;
&#xD;
          -  History of uncontrolled bronchial asthma&#xD;
&#xD;
          -  Patients with interstitial pneumonitis or pulmonary fibrosis&#xD;
&#xD;
          -  Patients with known brain metastasis&#xD;
&#xD;
          -  History of acute or subacute intestinal occlusion or chronic inflammatory bowel&#xD;
             disease or chronic diarrhoea&#xD;
&#xD;
          -  Symptomatic peritoneal carcinomatosis&#xD;
&#xD;
          -  Severe, non-healing wounds, ulcers or bone fractures&#xD;
&#xD;
          -  Patients with acute or chronic infection requiring systemic therapy&#xD;
&#xD;
          -  Known history of positive testing for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS)&#xD;
&#xD;
          -  Active or chronic Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection&#xD;
             (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive;&#xD;
             serologic tests required in patients who receive study treatment).&#xD;
&#xD;
          -  Known DPD deficiency (specific screening not required)&#xD;
&#xD;
          -  Known glucuronidation deficiency (Gilbert's syndrome);(specific screening not required&#xD;
&#xD;
          -  Treatment with sorivudine or brivudine within 28 days before study enrollment or&#xD;
             requirement for concomitant antiviral treatment with sorivudine or brivudine&#xD;
&#xD;
          -  History of a second primary malignancy during the past 5 years before inclusion in the&#xD;
             study or during participation in the study, with the exception of a basal cell or&#xD;
             squamous cell carcinoma of the skin or cervical carcinoma in situ, if these were&#xD;
             treated curatively.&#xD;
&#xD;
          -  Known previous or ongoing alcohol or drug abuse&#xD;
&#xD;
          -  Pregnant or breast-feeding patients&#xD;
&#xD;
          -  Any other severe concomitant disease or disorder which, in the investigator's opinion,&#xD;
             could influence the patient's ability to participate in the study or influence his/her&#xD;
             safety during the study or interfere with interpretation of study results&#xD;
&#xD;
          -  Both, absent and restricted legal capacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominik Modest, PD Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Ludwigs Maximilians University Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volker Heinemann, Prof. Dr.</last_name>
    <phone>+49 89 4400</phone>
    <phone_ext>0</phone_ext>
    <email>volker.heinemann@med.med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sebastian Stintzing, Prof. Dr.</last_name>
    <phone>+49 30 45051</phone>
    <phone_ext>3002</phone_ext>
    <email>sebastian.stintzing@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ludwigs Maximialians University</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Volker Heinemann, Prof. Dr.</last_name>
      <phone>+49 89 4400</phone>
      <phone_ext>0</phone_ext>
      <email>volker.heinemann@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Dominik Modest, PD Dr.</last_name>
      <phone>+49 89 4400</phone>
      <phone_ext>0</phone_ext>
      <email>dominik.modest@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Volker Heinemann, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominik Modest, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Volker Heinemann</investigator_full_name>
    <investigator_title>Director of the CCC-Munich at the LMU Munich</investigator_title>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>FIRE</keyword>
  <keyword>low-RAS</keyword>
  <keyword>mCRC</keyword>
  <keyword>Panitumumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

